Top 50 Life Science Startup Investors in Switzerland (August 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Zürcher Kantonal Bank
VC Fund
|
9 | Switzerland, Germany, Japan | Seed, Series A, Series B | Health Care, Biotechnology, Medical Device | $1.2M–$20M |
|
Foundation for Innovation and Technology (FIT)
VC Fund
|
7 | Switzerland, France, United States | Debt Financing, Grant, Seed | Health Care, Biotechnology, Artificial Intelligence | $13k–$1.1M |
|
Verve Ventures
VC Fund
|
5 | Switzerland, Germany, France | Series A, Seed, Series B | Health Care, Software, Biotechnology | $1.4M–$45M |
|
M Ventures
VC Fund
|
4 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
Eclosion SA
VC Fund
|
4 | Switzerland | Seed, Series C | Biotechnology, Pharmaceutical, Health Care | $1.6M–$28M |
|
EQT Life Sciences
VC Fund
|
4 | United States, The Netherlands, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $7.3M–$165M |
|
White Loop Capital
VC Fund
|
3 | France, Canada, Switzerland | Seed, Series A, Pre-Seed | Software, Blockchain, Cryptocurrency | $1M–$27M |
|
Andrew Keys
Angel
|
3 | United States, India, Norway | Seed, Pre-Seed, Series A | Software, Finance, Blockchain | $1M–$34M |
|
FAST — by GETTYLAB
VC Fund
|
3 | United States, United Kingdom, France | Pre-Seed, Seed | Software, Artificial Intelligence, Health Care | $125k–$7.6M |
|
Pfizer Venture Investments
VC Fund
|
3 | United States, United Kingdom, Switzerland | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $10M–$120M |
|
Kinled Holding
VC Fund
|
3 | United Kingdom, United States, Switzerland | Seed, Series A | Biotechnology, Health Care, Software | $594k–$40M |
|
Lakestar
VC Fund
|
3 | Germany, United States, United Kingdom | Seed, Series A, Series B | Software, Artificial Intelligence, FinTech | $2.4M–$91M |
|
Novartis Venture Fund
VC Fund
|
3 | United States, Switzerland, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $5.1M–$120M |
|
Versant Ventures
VC Fund
|
3 | United States, Switzerland, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $5M–$108M |
|
Lichtsteiner Foundation
VC Fund
|
2 | Switzerland | Seed, Series A | Biotechnology, Health Care, Medical | $1.6M–$6.8M |
|
Founderful
VC Fund
|
2 | Switzerland, United Kingdom, Canada | Pre-Seed, Seed, Series A | Software, Artificial Intelligence, Information Technology | $1.2M–$24M |
|
LASP Capital
VC Fund
|
2 | Brazil, Switzerland, United States | Seed, Series A, Pre-Seed | Artificial Intelligence, FinTech, Software | $800k–$31M |
|
VINCI CAPITAL
VC Fund
|
2 | Switzerland, Germany | Series A, Series B | Medical, Health Care, Biotechnology | $8.6M–$36M |
|
Amino Collective
VC Fund
|
2 | United States, United Kingdom, Germany | Seed, Series A, Pre-Seed | Biotechnology, Health Care, Artificial Intelligence | $125k–$37M |
|
Indaco Venture Partners
VC Fund
|
2 | Italy, United Kingdom, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Life Science | $3.3M–$110M |
|
ACE Ventures
VC Fund
|
2 | Switzerland, United States, United Kingdom | Seed, Series A, Pre-Seed | Information Technology, Artificial Intelligence, Life Science | $5M–$18M |
|
HTGF (High-Tech Gruenderfonds)
VC Fund
|
2 | Germany, Switzerland, United States | Seed, Series A | Software, Biotechnology, Information Technology | $909k–$39M |
|
SOSV
VC Fund
|
2 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
Boost VC
VC Fund
|
2 | United States, Canada, United Kingdom | Seed, Pre-Seed, Venture - Series Unknown | Software, Artificial Intelligence, Blockchain | $105k–$6.7M |
|
Rheingau Founders
VC Fund
|
2 | Germany, United States, Poland | Seed, Series A, Pre-Seed | Software, E-Commerce, Internet | $110k–$14M |
|
NEST pension fund
VC Fund
|
2 | Switzerland | Seed, Series A | Health Care, Life Science, Biotechnology | $2.1M–$3.5M |
|
EFI Lake Geneva Ventures
VC Fund
|
2 | Switzerland, Germany | Seed, Series B, Pre-Seed | Health Care, Life Science, Biotechnology | $2.5M–$16M |
|
Fongit Seed Invest
VC Fund
|
2 | Switzerland | Seed, Series A, Series B | Health Care, Medical, Biotechnology | $1.2M–$3.7M |
|
SICTIC
VC Fund
|
2 | Switzerland, Germany, Tanzania | Seed, Pre-Seed | Software, Artificial Intelligence, Information Technology | $302k–$3.4M |
|
Inflection
VC Fund
|
2 | United States, Germany, United Kingdom | Seed, Pre-Seed | Blockchain, Cryptocurrency, Software | $500k–$13M |
|
S2S Ventures
VC Fund
|
2 | Switzerland, Germany | Pre-Seed, Seed | Health Care, Artificial Intelligence, Manufacturing | $28k–$3.4M |
|
OCCIDENT
VC Fund
|
2 | Switzerland, Germany, Finland | Series A, Seed, Series B | Health Care, Biotechnology, Medical Device | $874k–$139M |
|
Shine Capital
VC Fund
|
2 | United States, Spain, Canada | Seed, Series A, Series B | Software, Artificial Intelligence, Information Technology | $3.5M–$71M |
|
1kx
VC Fund
|
2 | United States, Germany, Switzerland | Seed, Series A, Venture - Series Unknown | Blockchain, Cryptocurrency, Software | $1.8M–$34M |
|
BlueOcean Ventures
VC Fund
|
2 | Switzerland, India, France | Seed, Series A, Series B | Health Care, Medical, Personal Health | $1M–$20M |
|
Mergus Ventures
VC Fund
|
2 | Brazil, United States, Chile | Seed, Pre-Seed, Angel | Aerospace, AgTech, Biotechnology | $200k–$11M |
|
Omega Funds
VC Fund
|
2 | United States, Switzerland, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $14M–$208M |
|
Excellis
VC Fund
|
2 | Switzerland, United Kingdom | Seed, Series A, Series B | Health Care, Internet of Things, Medical | $1.3M–$14M |
|
Zee Prime Capital
VC Fund
|
2 | United States, United Kingdom, Singapore | Seed, Series A | Blockchain, Cryptocurrency, Information Technology | $2M–$43M |
|
Kickfund
VC Fund
|
2 | Switzerland, Germany | Seed, Pre-Seed, Convertible Note | Biotechnology, Health Care, Manufacturing | $110k–$5.7M |
|
Sunstone Life Science Ventures
VC Fund
|
2 | Denmark, Sweden, Switzerland | Series A, Series B | Biotechnology, Health Care, Medical | $5.5M–$52M |
|
BioMedPartners
VC Fund
|
2 | Switzerland, Germany, France | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $4.9M–$75M |
|
Skyviews Life Science
VC Fund
|
1 | United States, Switzerland, United Kingdom | Series B, Series A, Seed | Biotechnology, Food and Beverage, Medical | |
|
Bruker
VC Fund
|
1 | United States, Switzerland | Series A, Seed | Biotechnology, Medical, Health Care | |
|
Primal Capital
VC Fund
|
1 | Japan, Spain, Switzerland | Seed, Pre-Seed | Software, Information Technology, Internet | |
|
LongeVC
VC Fund
|
1 | United States, Estonia, Hong Kong | Seed, Series A | Biotechnology, Health Care, Therapeutics | |
|
Recipharm Venture Fund
VC Fund
|
1 | Sweden, Switzerland | Series A | Biotechnology, Medical, Health Care | |
|
Privilège Ventures
VC Fund
|
1 | Switzerland, Italy, France | Seed, Series A | Software, Health Care, Hardware | $1.2M–$7M |
|
Polytech Ventures
VC Fund
|
1 | Switzerland, United States, Spain | Seed, Series A | Financial Services, FinTech, Software | $1M–$9.7M |
|
FiveT Capital AG
VC Fund
|
1 | United States, Switzerland | Seed, Convertible Note, Initial Coin Offering | FinTech, Software, Health Care | |
| Access all 259 investors in Switzerland Life Science startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Zürcher Kantonalbank is an independent, incorporated public-law institution is its public service mandate. Enshrined in law, it governs the bank's economic, social, and environmental commitment.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Seed, Series A, Series B
- Geography: Switzerland, Germany, Japan
Investor stats
- Total investments: 200
- Round size: Seed $1.2M–$6M; Series A $2.3M–$13M; Series B $1.9M–$20M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- Riverkin — Riverkin builds rugged, low-cost water sensor systems for rivers that measure turbidity and temperature in real time. Our platform turns field data into clear insights and decision making tools.
- QualySense — QualySense is a Swiss start-up company focused on innovative high-throughput grain, beans and seeds sorting technology. QualySense develops a high-speed multi-tons per hour sorting device, which will change how grains, beans and seeds are processed and valued worldwide by assessing the biochemical quality of grains one by one. The QualySensesorters will enable customers to separate grain batches into different biochemical quality classes and sell the corresponding premium products at higher average prices. Food processors will be able to considerably increase the production value, and produce higher quality products in a non-interrupted process.
- Pearltec AG — Headquartered in Schlieren / Zurich, Pearltec AG develops, produces and delivers solutions for the optimal storage, fixation and positioning of patients. Their products are based on unique, patented technology developed in collaboration with ETH Zurich and renowned university hospitals.They have set theirselves the goal to use the technologycompetence of Pearltec AG for the benefit of humans, animals and industry and to create added value for their customers by excellent quality and convincing application advantages.Pearltec AG is certified according to ISO standard 13485. This certification certifies that their quality management system for the development and manufacture of medical devices meets the highest international standards.
The Foundation for Technology Innovation gives financial assistance to creative and technological projects at various phases of development. FIT funds projects in energy and the environment, information and digital technology, life sciences and health, precision industries, and nutrition and agriculture.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Artificial Intelligence
- Stage:Debt Financing, Grant, Seed
- Geography: Switzerland, France, United States
Investor stats
- Total investments: 204
- Round size: Seed $117k–$1.1M; Grant $13k–$125k; Debt Financing $100k–$566k
- Lead/follow: 93% lead, 7% follow
Portfolio highlights
- MyStones — MyStones - the athlete-centric platform redefining track and field. Daily progress into clear, shareable insights.
- Skilder Ai — skilder is the Agent Skills Management Platform to govern AI across Claude, ChatGPT and Copilot. Sovereign hosting, full governance, vendor-agnostic.
- Isospec Analytics — Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are unlocking the potential of glycomics and metabolomics in disease biomarker discovery and for the development of safer nutritional and pharmaceutical products.
Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: Switzerland, Germany, France
Investor stats
- Total investments: 285
- Round size: Seed $1.4M–$11M; Series A $2.3M–$18M; Series B $4.2M–$45M
- Lead/follow: 13% lead, 87% follow
- Last fund: Likely still investing — raised $66M in 2022
Portfolio highlights
- Axelera AI — Axelera AI is a company that delivers purpose-built hardware and software platforms designed to accelerate artificial intelligence tasks, particularly in edge computing. The company's flagship product, the Metis™ AI Platform, integrates both hardware and software components to deliver high-performance, energy-efficient AI inference solutions.This platform has been recognized for its innovation, notably being named a CES® 2024 Innovation Awards Honoree.Incubated in 2019 by the emerging technologies leader Bitfury and joined by the leading nano-technology group imec in early 2020, Axelera AI launched as a new company in 2021. Headquartered in the AI Innovation Center of the High Tech Campus in Eindhoven, Axelera AI has R&D offices in Belgium, Switzerland, and Italy. Its team of experts in AI software and hardware hail from top AI firms and Fortune 500 companies.
- Aylight — Aylight develops semiconductor laser and photonics platforms designed to improve optical connectivity in AI datacenters and related infrastructure. The company focuses on frequency modulated comb laser technology that generates multiple stable wavelengths from a single InP-based laser cavity. Its architecture produces an equidistant, RF-lockedwavelength grid that aligns with dense wavelength-division multiplexing requirements and reduces control complexity and power consumption. Aylight targets use cases in AI datacenter interconnects, quantum computing hardware, precision metrology, and communication equipment. Its products aim to integrate with terabit optical links and wavelength-division multiplexing systems while remaining compatible with existing fabrication processes.
- Atana Elements — Atana is a data-driven resource company that accelerates the exploration and development of flowing critical minerals.
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 174
- Round size: Seed $2.4M–$24M; Series A $5.6M–$50M; Series B $15M–$100M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Cyllene Therapeutics — EG 427 is a French biotechnology company that pioneers a new approach in gene therapy called pinpoint gene therapy.
- iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
- ApoGen Biotechnologies — Explore fast payout casinos that deliver winnings instantly or under 24 hours. List of the best payout casinos to get same day winnings.
Eclosion assists entrepreneurs with the necessary resources to bridge the gap between their laboratories and the stage where the start-up
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Health Care
- Stage:Seed, Series C
- Geography: Switzerland
Investor stats
- Total investments: 16
- Round size: Seed $1.6M–$2.7M; Series C $20M–$28M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- KYLYS — KYLYS is an innovative Swiss company based in Geneva founded in March 2017. KYLYS provides people and patients with highly effective and safe products based on biomolecules.
- Genkyotex — Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
- MPC Therapeutics — MPC Therapeutics develops a novel class of compounds with application in Immunotherapy and Metabolic diseases
Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, The Netherlands, Switzerland
Investor stats
- Total investments: 184
- Round size: Series A $7.3M–$78M; Series B $12M–$110M; Series C $12M–$165M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $266M in 2023
Portfolio highlights
- ActoGeniX — ActoGeniX is a biopharmaceutical company focused on the development and commercialization of a range of biological drugs. ActoGeniX was founded by Bernard Coulie and Mark Vaeck in 2006 and is based in Zwijnaarde, Belgium.
- Neurent Medical — Discover NEUROMARK, a minimally invasive solution for Chronic Rhinitis that targets the posterior nasal nerve to provide lasting symptom relief.
- Rotation Medical — Rotation Medical Inc. manufactures and markets a collagen scaffold for rotational cuff disease in Minnesota. The company was formerly known as Denali Medical Inc. and changed its name to Rotation Medical Inc. in March 2010. Rotation Medical was founded in 2009 and headquartered in Plymouth, Minnesota.
White Loop Capital is the first investment firm specialized in crypto-assets in France. Accompanying those who dare.
Show more...Investment focus
- Industry: Software, Blockchain, Cryptocurrency
- Stage:Seed, Series A, Pre-Seed
- Geography: France, Canada, Switzerland
Investor stats
- Total investments: 22
- Round size: Seed $1M–$1M; Pre-Seed $1.2M–$1.2M; Series A $10M–$27M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- ether.fi — EtherFi is a non-custodial decentralized ETH staking method that distributes staking to node operators in exchange for rewards.
- Usual — Usual Labs operates as a decentralized finance(DeFi) protocol.
- LayerZero Labs — An omnichain interoperability protocol. LayerZero enables the realization of cross-chain applications with a low level communication primitive.
Andrew Keys is the Co-Founder and Managing Partner of Andrew Keys. He previously worked for ConsenSys as a Head of Global Business Development. Andrew Keys attended Loyola University Maryland.
Show more...Investment focus
- Industry: Software, Finance, Blockchain
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, India, Norway
Investor stats
- Total investments: 14
- Round size: Seed $1M–$34M; Pre-Seed $1.4M–$2.5M; Series A $14M–$15M
- Lead/follow: 7% lead, 93% follow
Portfolio highlights
- Stackr Labs — Micro-rollups to scale web3 applications
- Zivoe Finance — Join Zivoe in disrupting predatory high-interest lending.
- Ithaca Finance — Ithaca Finance a cross-chain derivatives trading and settlements protocol, is composed of an on-chain settlement layer with an innovative off-chain matching engine.
Backing engineers building awe, wonder, speed.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Pre-Seed, Seed
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 108
- Round size: Seed $500k–$7.6M; Pre-Seed $125k–$2.3M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Modelwise — Automated functional safety analysis via drag & drop. Seamless Integration. Faster Analyses. Zero Defects. More Savings.
- Fluent Metal — Fluent Metal is a company that makes metal 3D printing economical, efficient, and safe.
- Integrated Reasoning — Integrated Reasoning builds computer hardware to efficiently solve optimization problems. We're making it faster and cheaper to solve problems like scheduling airline pilots or packing boxes into trucks.
Pfizer Venture Investments is a corporate venture capital firm that invests in areas of current or future strategic interest to Pfizer. It aims to remain at the forefront of life science advances. It identifies and invests in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’spipeline and shape the future of its industry.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 179
- Round size: Series A $10M–$100M; Series B $20M–$120M; Series C $15M–$102M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $600M in 2018
Portfolio highlights
- Ixchelsis — Ixchelsis Ltd is a clinical-stage biotechnology company developing an oxytocin receptor antagonist (IX-01) for the treatment of premature ejaculation (PE). IX-01 is a clinical stage asset that has the potential to be the best in class pharmacological approach for the treatment of PE. To date IX-01 has completed a Phase 1 single ascending dose studyin healthy male volunteers and is currently being progressed through to clinical proof of concept (POC). Ixchelsis is funded by TVM Life Sciences Ventures VII and is lead by an excellent Management team with extensive experience in pharmaceutical R&D, particularly in the male sexual health therapeutic area.
- Flare Therapeutics — Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation.
- Flexion Therapeutics — Flexion Therapeutics advances drug candidates through clinical proof of concept and beyond, in partnership with pharmaceutical and biotechnology companies. By providing expertise and sharing risk, Flexion effectively expands the portfolios of its partners.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Kinled was founded in 1980 to retain the investment assets of the Aisher family.In 1990, the investment focus shifted to a portfolio of early stage investments applying Kinled’s company development experience alongside the endurance and passion of family owned investments together with the strategic focus of venture capitalists.Since then,Kinled has taken 8 companies to public markets and many more to successful trade sales at significant multiples.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Switzerland
Investor stats
- Total investments: 139
- Round size: Seed $594k–$14M; Series A $1.7M–$40M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Esper — Esper is the first cloud-based platform to help governments proactively manage public policy with better data and transparency.
- Varda — Expanding the economic bounds of humankind with the world's first orbital manufacturing & reentry platform.
- TAG Therapeutics — TAG Therapeutics develops precision medicine approaches for telomere pathologies and aging-related diseases, such as Idiopathic Pulmonary Fibrosis and Short Telomere Syndromes
Lakestar invests in founders and technologies shaping Europe's future, helping build resilience, sovereignty, and long-term growth in a changing world.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, FinTech
- Stage:Seed, Series A, Series B
- Geography: Germany, United States, United Kingdom
Investor stats
- Total investments: 236
- Round size: Seed $2.4M–$17M; Series A $6.6M–$75M; Series B $16M–$91M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- Swan — Use Swan's APIs to embed white-labeled banking features like accounts, cards, and IBANs into your workflows and UX.
- Vertice — The SaaS purchasing platform that gives finance leaders cost control, efficiency and flexibility.
- Cambridge Aerospace — Our mission is to eliminate the risk of existential war in Europe.
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 219
- Round size: Series A $5.1M–$81M; Series B $11M–$120M; Series C $9M–$75M
- Lead/follow: 26% lead, 74% follow
- Last fund: May invest from a new fund soon — raised $200M in 2009
Portfolio highlights
- Bionano Genomics — Discover how Bionano is striving to elevate health and wellness for all through optical genome mapping (OGM) solutions that transform the way the world sees the genome.
- Protego Biopharma — Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California.
- Twentyeight-Seven Therapeutics — Maxslot88 merupakan link situs slot gacor gampang menang jackpot maxwin hari ini sebagai daftar apk slot88 terpercaya dengan server thailand resmi, memberikan pengalaman bermain slot online yang aman dan menghibur bagi semua klien.
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, Canada
Investor stats
- Total investments: 296
- Round size: Series A $5M–$72M; Series B $10M–$107M; Series C $12M–$108M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Graphite Bio — Graphite Bio is a next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases
- Dayra Therapeutics — Dayra Therapeutics manufactures peptide based medicines.
- Jecure Therapeutics — Jecure Therapeutics is focused on the discovery of innovative therapeutics for the treatment of non-alcoholic steatohepatitis.
Boosting health pioneers. We invest in early stage start-ups in different sectors: medtech, life science, biotech, mental health, public health, well-being.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: Switzerland
Investor stats
- Total investments: 11
- Round size: Seed $1.6M–$6.8M
- Lead/follow: 9% lead, 91% follow
Portfolio highlights
- Hemostod — Developing universal platelets and next-generation diagnostics
- DigeHealth — DigeHealth's approach to monitoring gut health using bowel noises and body measurements could provide some really valuable insights into digestive well-being.
- Allegria Therapeutics — Allegria Therapeutics operates as a biotech company.
Founderful operates as a venture capital firm and a Switzerland’s leading pre-seed fund.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Pre-Seed, Seed, Series A
- Geography: Switzerland, United Kingdom, Canada
Investor stats
- Total investments: 105
- Round size: Seed $1.5M–$14M; Pre-Seed $1.2M–$4.3M; Series A $3.4M–$24M
- Lead/follow: 56% lead, 44% follow
- Last fund: Likely still investing — raised $85M in 2024
Portfolio highlights
- AVIAN — AVIAN helps industrial teams prevent fires and downtime with continuous thermal monitoring, abnormal-heat detection, alerts, and response workflows.
- Stellar Alpina — Stellar Alpina develops modular lunar landers and the RDRE propulsion modules that power them, combining rapid hardware iteration with a scalable platform approach for reliable missions from Earth orbit to the Moon.
- Exclaim Robotics — Autonomous mobile robots for the AI data center.
LASP Capital is a investment firm focuses on global growth companies.
Show more...Investment focus
- Industry: Artificial Intelligence, FinTech, Software
- Stage:Seed, Series A, Pre-Seed
- Geography: Brazil, Switzerland, United States
Investor stats
- Total investments: 29
- Round size: Seed $800k–$6M; Pre-Seed $2.4M–$5.3M; Series A $6.5M–$31M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Kaya Pay — Track owner-furnished materials from procurement through delivery, installation, and turnover.
- Nuvia — Nuvia is an artificial Intelligence automation platform that helps with sales process, lead generation and hyper-personalized conversions
- Neofin — AI-powered software for B2B payments workflows that automates and streamlines financial processes, transforming the way companies get paid and pay their bills
Vinci Capital is a leading Swiss private equity firm with over MCHF 200 under management. Since 1998 they have provided equity to over 30 Swiss technology and industrial companies to finance innovation, growth and succession-buyouts.Their investment team capitalizes on 40 years of cumulated experience in private equity and a solid operationalbackground in growth, turn-around, consolidation, IPOs and M&A situations.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Series B
- Geography: Switzerland, Germany
Investor stats
- Total investments: 15
- Round size: Series A $8.6M–$20M; Series B $21M–$36M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $10M in 2012
Portfolio highlights
- Anergis — Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne inSwitzerland.
- SENSIMED — Sensimed designs, develops, and commercializes integrated micro-systems for medical devices. The company’s product portfolio includes SENSIMED Triggerfish, a product that offers an automated recoding of continuous ocular dimensional change over 24 hours. Sensimed is now focused on expanding the knowledge of how this individual data can best beused in the clinical setting to deliver customized treatment. The 24 hour profiles are being centralized on a registry together with patient and treatment information. The data is being analyzed and modeled on an ongoing basis in an attempt to identifying pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy following treatment.Sensimed was founded by Matteo Leonardi and Sacha Cerboni in August 2003 and is based in Lausanne, Switzerland.
- beqom — beqom is a Total Compensation Management Software Solution focused exclusively on managing compensation & performance for HR & Sales.
Amino Collective is an institutional venture capital firm investing at seed stage in health and bio companies. They help bring life-changing ideas to life by backing, connecting, and advancing our collective of entrepreneurs and scientists. The firm intends to invest in the sectors of biology, biotech, health tech, science, digital health, lifescience, and synthetic biology.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Artificial Intelligence
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 45
- Round size: Seed $2.4M–$14M; Pre-Seed $125k–$7.8M; Series A $12M–$37M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Calibre — Diagnostic testing, clinicians, and AI working together to help you deeply understand your health and how to improve it.
- Modern Relay — Modern Relay provides context graph for enterprise AI.
- Theorema — Autonomous R&D agents for biotech, pharma, chemicals, and materials. Theorema analyzes data, recovers R&D costs, and accelerates discovery. #1 on BixBench.
VENTURE We invest across all sectors with specific focus on technology and digital The largest independent more About Us Portfolio [...]
Show more...Investment focus
- Industry: Biotechnology, Health Care, Life Science
- Stage:Series A, Series B, Series C
- Geography: Italy, United Kingdom, Switzerland
Investor stats
- Total investments: 47
- Round size: Series A $3.3M–$31M; Series B $8.8M–$89M; Series C $16M–$110M
- Lead/follow: 34% lead, 66% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- Newcleo — newcleo is the clean and safe nuclear technology company. Privately funded and headquartered in London, UK, newcleo was launched in 2021 to be a disruptor in the field of nuclear energy. Its mission is to generate safe, clean and inexhaustible energy for the world, through a radically innovative combination of existing, accessible technologies.newcleo is building the next generation system with the goals to: (1) eliminate the need for geological repositories by using a fast neutron flux avoiding production of long life radioactive elements; (2) develop an Accelerator Driven System (ADS), based on the intrinsically safe coupling of a particle accelerator and a sub-critical reactor; (3) accelerate the development of new fuel cycles, including thorium, that provide economic, clean, safe and inexhaustible energy from nuclei and the opportunity to burn the long-lived nuclear waste produced by the old generation of nuclear reactors.With visionary co-founders, newcleo brings together a team of engineers with deep knowledge of nuclear energy with younger recruits with a fresh mindset, working to design an innovative micro Lead Fast Reactor with significant commercial applications, for example in shipping. newcleo wants to be the first step toward the evolution of its industry to become fully respectful of people and the environment. To develop a new, sustainable, and completely safe way of generating nuclear energy that will lead humanity to zero emissions, and to the mitigation of global warming.
- Easy Rain — Leading a new automotive era: our modular ecosystem of virtual sensors and active hardware makes cars and autonomous platforms truly safe in every condition.
- Iama Therapeutics — At IAMA Therapeutics, we are constantly pushing the boundaries of neuroscience drug discovery to develop new medicines and make a difference in the lives of children suffering from brain disorders and their families. Our purpose is to provide a therapeutic solution to children suffering from neurological conditions and provide their families withthe support they need.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!ACE Ventures is a Swiss-based, early-stage VC firm partnering with the next generation of Swiss tech founders who are building transformative businesses, both in Switzerland and abroad.
Show more...Investment focus
- Industry: Information Technology, Artificial Intelligence, Life Science
- Stage:Seed, Series A, Pre-Seed
- Geography: Switzerland, United States, United Kingdom
Investor stats
- Total investments: 7
- Round size: Seed $5M–$8M; Series A $6M–$18M
- Lead/follow: 71% lead, 29% follow
Portfolio highlights
- Veezoo — Veezoo empowers individuals to find actionable insights from data by literally just asking questions in plain English!
- Scholé — AI-native personalized learning
- Adaptyv Biosystems — Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and nanofluidics.
High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Series A
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 610
- Round size: Seed $909k–$7M; Series A $3.5M–$39M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — raised $522M in 2022
Portfolio highlights
- CorTec — Reliable products for active implantable device development. We realize your next project with you and offer individual solutions that meet your specific requirements for Medical Devices, especially in neurotechnology.
- Coinlend — Coinlend - The Lending-Bot for Bitfinex & Liquid Genearate interest from your Bitcoin and Altcoin investments!
- CenterPoint - Connective Software Engineering — CenterPoint was founded in 2000 and is based in Villach, Austria with an additional office in Warsaw, Poland. CenterPoint - Connective Software Engineering develops and markets process control and fault detection and classification software solutions. The company offers cause effect analysis, metrology assessment, and close loop and run to runcontrol services. It's focus are the semiconductors, electronics, and steel and alloy industries.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1482
- Lead/follow: no public data
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Boost VC: The Pre-Seed Fund Making Sci-FI a Reality. Investing in crypto, virtual reality, augmented reality, AI, Ocean Tech, Space Tech, human augmentation, exoskeletons and more.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Blockchain
- Stage:Seed, Pre-Seed, Venture - Series Unknown
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 318
- Round size: Seed $406k–$6.7M; Pre-Seed $105k–$3M; Venture - Series Unknown $1.7M–$5M
- Lead/follow: 16% lead, 84% follow
- Last fund: Likely still investing — raised $100M in 2022
Portfolio highlights
- Claryx — The hospital immune system. Claryx detects each infection, traces how it's spreading, recommends a response, and confirms that it's gone.
- SkinBit — SkinBit is a healthtech company that develops AI-powered skin cancer detection, digital mapping, and health monitoring solutions.
- Polkadot — Products for People.
Rheingau Founders is a Berlin&Munich based Venture Capital firm active since 2011. Focusing on pre-seed to Series A investments in Europe, predominantly B2B in the fields of Marketplaces, Software as a Service, InsurTech, and eHealth. Rheingau targets start-ups that have the potential to sustainably disrupt existing processes and value chains.Besides the financial investment, we offer strategic support through the mentorship of our partners.
Show more...Investment focus
- Industry: Software, E-Commerce, Internet
- Stage:Seed, Series A, Pre-Seed
- Geography: Germany, United States, Poland
Investor stats
- Total investments: 85
- Round size: Seed $110k–$6.3M; Pre-Seed $770k–$2.7M; Series A $2.4M–$14M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- MoleQlar — MoleQlar is a data and research-driven longevity company. It provides valuable information and offers consumers lab-tested nutritional supplements. The company focuses on functional medicine with optimized nutrition. Their product range includes Uthever NMN, Resveratrol, Betaine, Carnosine, and more. These products are aimed at lowering biologicalage and promoting health and longevity. MoleQlar also offers health tracking services. The company is certified in Germany and delivers its products EU-wide, including Switzerland.
- Qualifyze — Qualifyze (former ChemSquare) was founded out of the Technical University of Darmstadt in September 2017. Today, we are based in Frankfurt am Main, the heart of Germany’s pharmaceutical cluster, where the leading life science companies are based. Our team consists of 16 people with diverse backgrounds and areas of expertise in business,engineering, and technology as well as several strategic partners from the pharma, food and cosmetics industry.
- Akhetonics — Akhetonics is a photonic computing company building all-optical processors for ultra-fast AI and high-performance computing. It is a deep-tech semiconductor company focused on photonic (light-based) computing hardware. It develops all-optical processors designed to accelerate AI, reasoning, and complex computational workloads. The company aims todeliver ultra-fast, energy-efficient computing beyond traditional electronic chips.
For more than 35 years, Nest, as the first ecological and ethical pension fund in Switzerland, has remained true to its guiding principle: the optimal provision for the companies affiliated with us and their employees.
Show more...Investment focus
- Industry: Health Care, Life Science, Biotechnology
- Stage:Seed, Series A
- Geography: Switzerland
Investor stats
- Total investments: 3
- Round size: Seed $2.1M–$3.5M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Piomic — There are about 50 million reported cases of patients suffering from hard-to-heal wounds, which has created a severe cost burden on global healthcare systems.The COMS® One Therapy System is a portable, hand-held device which incorporates the technologies for optical and magnetic stimulation, intended to promote wound healing in chronic leg andfoot ulcers.The pivotal clinical study showed that the treatment is safe, leads to accelerated wound closure, overall reduced pain and increased quality of life. The easy-to-use, single button operated device integrates smoothly into the patient’s healing journey with usage in stationary and ambulant facilities but also in patient’s home.By developing a therapy which is safe and effective we hope to set a better future for patients in need.
- Comphya — Comphya developing an active implantable medical device to restore the erectile function of patient non-responsive to oral drugs.
- Nagi Bioscience — Enabling small organisms testing to any lab. Unleash unique datapoints efficiently at a high-throughput rate.
EFI Lake Geneva Ventures is a seed and early-stage investment strategy based in Geneva, Switzerland. Founded in 2020, our mission is to foster innovation by investing at an early stage in fast-growing innovative Swiss companies in Technology, Life Sciences and Medtech.
Show more...Investment focus
- Industry: Health Care, Life Science, Biotechnology
- Stage:Seed, Series B, Pre-Seed
- Geography: Switzerland, Germany
Investor stats
- Total investments: 7
- Round size: Seed $2.5M–$3.8M; Series B $5.1M–$16M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Hemotune — hemotune develops a revolutionary medical device for blood purification to provide the means to treat critically ill patients and save lives.
- Hylomorph — Hylomorph is a clinical-stage medical device company developing innovative materials designed to transform the biocompatibility of implantable medical devices.
- Annaida Technologies — Empowering fertility providers and researchers with AI-driven metabolomic platforms. Non-invasive, real-time insights at the microscale for personalized medical treatments.
Fongit Seed Invest (FSI) is the leading Seed Money Fund of Switzerland for young technology companies. It provides smart seed capital.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: Switzerland
Investor stats
- Total investments: 9
- Round size: Seed $1.2M–$1.4M; Series A $2.3M–$3.7M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- EBAMed — EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware andsoftware components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.
- Gmelius — Gmelius is the world's first 360 email collaboration platform designed for Gmail and your company's daily apps. Join the async movement!
- Annaida Technologies — Empowering fertility providers and researchers with AI-driven metabolomic platforms. Non-invasive, real-time insights at the microscale for personalized medical treatments.
SICTIC is the leading angel investor network in Switzerland with the largest Swiss seed-stage startup dealflow.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Pre-Seed
- Geography: Switzerland, Germany, Tanzania
Investor stats
- Total investments: 289
- Round size: Seed $537k–$3.4M; Pre-Seed $302k–$2.7M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Agrinorm — Agrinorm is a Swiss deep tech company leveraging cutting edge machine learning techniques for the optimization of fruits and veg supply chains.
- hypt — hypt is a Swiss based SaaS marketing solution that empowers companies to digitalize word-of-mouth. By using our word-of-mouth manager companies are able to activate 40% of their customers to send out a personal recommendation to their peers increasing sales through word-of-mouth by 4 times. Our solution empowers our ICP customers in the finance andinsurance segments to strategically use and optimize the most authentic and cost effective advertising channel – word-of-mouth – and makes it an accessible asset of every marketing mix.
- Carewell — Carewell is influencing the way people work in healthcare by providing flexible digital solutions tailored to their specific needs.
Inflection is a first check venture capital firm exploring new frontiers. We run nodes, govern DAOs and write code. We invest between $500k-$1.5M initially and have a global mandate.
Show more...Investment focus
- Industry: Blockchain, Cryptocurrency, Software
- Stage:Seed, Pre-Seed
- Geography: United States, Germany, United Kingdom
Investor stats
- Total investments: 44
- Round size: Seed $2M–$13M; Pre-Seed $500k–$4.3M
- Lead/follow: 23% lead, 77% follow
Portfolio highlights
- Ubitium — Ubiquitous computing, universal RISC-V microprocessor
- Nordic Air Defence — Nordic Air Defence builds cutting-edge solutions for modern aerial security. Made in Sweden.
- Fabric Cryptography — Building towards a trustless future with custom chips for advanced cryptography.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!S2S Ventures is a fully student-led VC fund from Switzerland, backed by some of the country's most successful entrepreneurs.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Manufacturing
- Stage:Pre-Seed, Seed
- Geography: Switzerland, Germany
Investor stats
- Total investments: 28
- Round size: Seed $954k–$3.4M; Pre-Seed $28k–$2.7M
- Lead/follow: 25% lead, 75% follow
- Last fund: Likely still investing — raised $13M in 2021
Portfolio highlights
- Haicker — AI code auditors. Cheaper than pentests, smart enough to spot your bad habits. Get Haicker now on https://t.co/rPLvJrB2jP
- Scanvio — Scanvio Medical provides gynecologists, endometriosis centers and ultrasound manufacturers with an AI-guided ultrasound software for faster endometriosis diagnosis.
- Forgis — Forgis is leading the next industrial revolution by introducing industrial intelligence into factories, which boosts the competitiveness of Western manufacturing.
Occident is an international, privately held investment company based in Zug and Munich. Our goal is to manage our own wealth in a sustainable, meaningful manner seeking to make a positive contribution to society through our investments. Venture Capital is the focus of our investment activities. We see ourselves as a long-term oriented enabler forinnovative start-ups and visionary founders. As a complementary team of experts, we are fascinated by technologically sound topics (deep tech) from the life sciences, digital and high-tech sectors with the potential to decisively improve people's lives.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Seed, Series B
- Geography: Switzerland, Germany, Finland
Investor stats
- Total investments: 36
- Round size: Seed $874k–$4.6M; Series A $2.1M–$12M; Series B $6.2M–$139M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Immitra Bio — Developing scalable in-vivo genomic medicine for blood disorders
- Lymphatica Medtech — Lymphatica Medtech is a medical device development company developing a minimally invasive solution for chronic lymphedema.Lymphedema is the chronic swelling that generally occurs in the arms or the legs.Lymphedema is most commonly caused by the removal of or the damage to the lymph nodes as a part of cancer treatment. It results from ablockage in the lymphatic system, which is part of the immune system. The blockage prevents the lymphatic system from draining excess fluids, and the fluid buildup leads to swelling, infections, and pain.Unfortunately, there is no cure for lymphedema. It can be managed with early diagnosis and diligent care of the affected limb, through daily compression, bandages, and manual drainage sessions. From the moment of the diagnosis, the life of lymphedema patients changes forever.Cancer and cancer-related interventions (i.e. surgery, radiotherapy) are frequent causes of lymphedema occurring both in the upper and lower limbs. Breast cancer survivors are at high risk for developing lymphedema, as well as patients treated for melanoma, pelvic and head and neck cancer or other cancer treatments that require lymph node dissection. Physical trauma can also result in lymphedema, a major cause of lymphatic disease among wounded veterans.Lymphedema is associated with significantly impaired quality of life, skin changes, increased risk of infection and in rare cases lymphedema itself may undergo malignant transformation.Lymphatica offers a permanent solution that will allow patients to regain their normal lifestyle.
- Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
Shine is an early-stage venture capital firm that partners with creative, convincing, relentless entrepreneurs to build iconic businesses.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Series A, Series B
- Geography: United States, Spain, Canada
Investor stats
- Total investments: 78
- Round size: Seed $3.5M–$21M; Series A $12M–$25M; Series B $10M–$71M
- Lead/follow: 38% lead, 62% follow
- Last fund: Likely still investing — raised $100M in 2022
Portfolio highlights
- Antares — Factory-produced, deployable fission microreactors to provide strategic energy for mission-critical systems across Earth, space, and underseas.
- Walden Robotics — Walden Robotics is an industrial robotics company that builds and deploys general-purpose, semi-humanoid robots for manufacturing and logistics.
- Turnout — Turnout Technologies is a technology related company.
1kx is a research-driven global investment firm making trust instant, open, and programmable, with 160+ investments since 2018 across DeFi, stablecoins, and onchain infrastructure.
Show more...Investment focus
- Industry: Blockchain, Cryptocurrency, Software
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: United States, Germany, Switzerland
Investor stats
- Total investments: 177
- Round size: Seed $1.8M–$11M; Series A $5M–$28M; Venture - Series Unknown $3M–$34M
- Lead/follow: 45% lead, 55% follow
Portfolio highlights
- EarnOS — EarnOS is the fully remote company that provides Global Ad & Payments Platform powered by Web3.
- KOR Protocol — KOR Protocol is a decentralized intellectual property (IP) infrastructure designed to empower creators, protect rights, and enable seamless collaboration and monetization of IP assets across various industries, including music, film, TV, gaming, and art. Backed by notable entities like Animoca Brands, Republic, Niantic, Sfermion, Solana, andprominent creators such as Black Mirror, Disclosure, deadmau5, and Richie Hawtin, KOR leverages blockchain, AI, and DeFi to offer a transparent, efficient, and scalable environment for IP expansion.
- Freehand — AI Teams for Complex Spend Management
BlueOcean Ventures SA provides capital, operational and company development advisory support (mentoring, company management, divestment experience, network, negotiation support) to entrepreneurs in Switzerland. BlueOcean Ventures is based in Geneva, Switzerland.
Show more...Investment focus
- Industry: Health Care, Medical, Personal Health
- Stage:Seed, Series A, Series B
- Geography: Switzerland, India, France
Investor stats
- Total investments: 17
- Round size: Seed $1M–$3.1M; Series A $2.3M–$20M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Augurix — Augurix was born out of the real-life experiences of living with Celiac Disease. In 2004, Cecile – a pediatrician with an MD and PhD in immunology – noticed her 18-month old son Simon exhibiting symptoms of the disease. As a professional and having been diagnosed herself some thirty years earlier, she was able to spot the early warning signs. ButCecile was also acutely aware that despite affecting almost 1 in 100 people, Celiac Disease was difficult to diagnose.Cecile and her husband Thierry became determined to find a way to change this, giving parents and their children the best chance of an accurate diagnosis and the ability to live their lives free of the often debilitating symptoms. Using Swiss medical expertise Augurix was founded in 2007, with a mission to provide primary care doctors with an easy-to-use, affordable tool, to lower the hurdle of diagnostics.In 2010 Simtomax® was launched – a rapid screening test for the early determination of Celiac Disease at the point-of-care – finally bringing Cecile’s vision to life. Today, Augurix is pursuing its vision by enlarging its diagnostics offer to other gastrointestinal diseases.
- official.fm — Music to discover and share.
- Rheon Medical — Rheon Medical manufactures eyeWatch, a drainage device for the treatment of glaucoma. It also offers control unit, an instrument that measures and adjusts the eyeWatch's functional position. Rheon Medical began operation in 2010. Its headquarters is in Lausanne in Switzerland.
Investing in unconventional founders solving challenges with cutting-edge, future-forward technologies.
Show more...Investment focus
- Industry: Aerospace, AgTech, Biotechnology
- Stage:Seed, Pre-Seed, Angel
- Geography: Brazil, United States, Chile
Investor stats
- Total investments: 28
- Round size: Seed $800k–$11M; Pre-Seed $200k–$500k
- Lead/follow: 7% lead, 93% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Spaceium — Building service stations along the space superhighway.
- Starcloud — Starcloud is building a network of megawatt-scale data centers in space, scaleable to gigawatt capacity. Falling launch costs allow Starcloud to take advantage of the abundant energy, passive cooling, and high-speed connectivity in space.
- Starcloud — Lumen Orbit provides in-orbit cloud computing and data relay for satellites.
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 161
- Round size: Series A $16M–$187M; Series B $37M–$162M; Series C $14M–$208M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Attenua — 100% satisfaction guaranteed. Hassle-free shopping. We help you find the right domain name.
- Andrew Alliance — OneLab is laboratory software to design and execute liquid handling protocols. Pipette+ for manual liquid handling pipetting and Andrew+ the pipetting robot
- Chord Therapeutics — Chord Therapeutics is a clinical stage pharmaceutical company developing drugs for patients with rare, life-threatening and severely disabling diseases. We are advancing our lead drug candidate CRD1 under orphan drug designation for the treatment of neuromyelitis optica spectrum disorders (NMOSD) and myasthenia gravis (MG).
Excellis is a private investment company focusing on Robotics Automation.
Show more...Investment focus
- Industry: Health Care, Internet of Things, Medical
- Stage:Seed, Series A, Series B
- Geography: Switzerland, United Kingdom
Investor stats
- Total investments: 10
- Round size: Seed $1.3M–$10M; Series A $5.8M–$14M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- FluoRok — By employing our patented technology, we can produce fluorochemicals without the production of toxic and highly dangerous hydrofluoric acid
- MintNeuro — MintNeuro is pioneering the use of semiconductor technology in next-generation neural implants.
- Annaida Technologies — Empowering fertility providers and researchers with AI-driven metabolomic platforms. Non-invasive, real-time insights at the microscale for personalized medical treatments.
Totally supercool and chilled VC investing in programmable assets, collaborative intelligence and other buzzwords.
Show more...Investment focus
- Industry: Blockchain, Cryptocurrency, Information Technology
- Stage:Seed, Series A
- Geography: United States, United Kingdom, Singapore
Investor stats
- Total investments: 95
- Round size: Seed $2M–$9M; Series A $5M–$43M
- Lead/follow: 2% lead, 98% follow
Portfolio highlights
- TrueDAO — TrueDAO is a new-generation AI-native decentralized autonomous financial infrastructure. Built on the underlying logic of DAO community co-governance, it leverages smart contracts to construct an on-chain financial system integrating AI algorithm scheduling, staking, and dynamic protection. It optimizes economic parameters and asset strategies inreal time via AI models, delivers low-volatility and sustainable value growth paths for digital assets, and pioneers an innovative paradigm of autonomous finance.
- Cryopets — Pausing biological time with cryosleep for pets
- Share — From subsea cables to last-mile networks, Share coordinates fragmented infrastructure into a single ecosystem.
Kickfund is a Venture Capital fund that systematically backs companies that successfully complete Venture Kick.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Manufacturing
- Stage:Seed, Pre-Seed, Convertible Note
- Geography: Switzerland, Germany
Investor stats
- Total investments: 49
- Round size: Seed $1.1M–$5.7M; Pre-Seed $335k–$4M; Convertible Note $110k–$118k
- Lead/follow: 16% lead, 84% follow
Portfolio highlights
- Immitra Bio — Developing scalable in-vivo genomic medicine for blood disorders
- Carewell — Carewell is influencing the way people work in healthcare by providing flexible digital solutions tailored to their specific needs.
- BLEEDnFIRE Therapeutics — BLEEDnFIRE Therapeutics: At BLEEDnFIRE Therapeutics, we are pioneering innovative siRNA-based therapies for hemophilia, Von Willebrand disease & other rare bleeding disorders (RBDs) by developing BnF-001. Our mission is to transform patient care and improve quand improve quality of life through targeted ...
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B
- Geography: Denmark, Sweden, Switzerland
Investor stats
- Total investments: 61
- Round size: Series A $5.5M–$44M; Series B $9.6M–$52M
- Lead/follow: 16% lead, 84% follow
- Last fund: May invest from a new fund soon — raised $94M in 2019
Portfolio highlights
- Step Pharma — Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe.
- Resalis Therapeutics — Resalis Therapeutics sviluppa un farmaco in grado di inibire un micro-RNA per il trattamento di alcune malattie metaboliche
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: Switzerland, Germany, France
Investor stats
- Total investments: 88
- Round size: Series A $5.3M–$31M; Series B $4.9M–$75M; Series C $5.8M–$47M
- Lead/follow: 34% lead, 66% follow
- Last fund: May invest from a new fund soon — raised $113M in 2018
Portfolio highlights
- T-CURX — T-CURX develops a new generation of T cells for personalized cancer immunotherapy, built on a proprietary platform that overcome challenges ...
- iDEL Therapeutics — iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism.
- ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
Skyviews Life Science is a privately held advisory company specialised in personalised health.
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, Medical
- Stage:Series B, Series A, Seed
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 14
- Lead/follow: no public data
Portfolio highlights
- one.bio — BCD Bioscience is an emerging biotechnology spinout from UC Davis that creates ingredients for food and biopharmaceutical applications. The company was founded in 2019 and is headquartered in Davis, California, United States.
- Volumina Medical — Volumina is active in the field of tissue engineering and develops injectable 3D scaffolds for the reconstruction of volumes of soft tissues (fat, muscles, glandular tissues, supporting and connective tissues) that have been lost after tumor ablation, disease, trauma, or for purely esthetically purposes.
- Vedanta Biosciences — Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Bruker Corporation is a provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Seed
- Geography: United States, Switzerland
Investor stats
- Total investments: 11
- Lead/follow: no public data
Portfolio highlights
- KIYATEC — Kiyatec is a functional precision oncology company that measures the response of individual patient live cancer cells with its innovative 3D cell culture technology platform. Kiyatec works with leading biopharmaceutical companies to unlock response dynamics for investigational drug candidates for use in solid tumors.
- Terrain Bio — Terrain Bio helps RNA therapeutics companies design and build better RNA, faster. Leveraging the latest innovations in protein and RNA design and the deep expertise of its scientific cofounders, Terrain brings unparalleled speed and quality to RNA manufacturing.
- Mercy BioAnalytics — We are making early stage cancer 100,000x easier to find using extracellular vesicles found in blood, specific to their parent cells.
Primal Capital, an independent venture capital " incubator bait fund at ", served as the Associate than July 2012 Hiroshi was Sasaki is the venture capital fund that serves as the representative partner. Representative of Sasaki, the seed acceleration program "Incubate Camp" operated by Incubate bait fund is carried out a totalof four times of planning and management than in 2012, They have also engaged in support operations of portfolio companies. - See more at: https://www.crunchbase.com/organization/primal-capital#sthash.m2z1DCbt.dpuf
Show more...Investment focus
- Industry: Software, Information Technology, Internet
- Stage:Seed, Pre-Seed
- Geography: Japan, Spain, Switzerland
Investor stats
- Total investments: 30
- Lead/follow: no public data
Portfolio highlights
- Hivello — Hivello is a Decentralized Physical Infrastructure Network aggregator. Contribute resources, connect with Web3 protocols, and effortlessly generate passive income.
- RemitAid — RemitAid is a fintech company that operates an overseas payment platform for cross-border transactions between companies.
- xCARE — xCARE specializes in the development and commercialization phases of the pharmaceutical and medical device industries.
With more than 30 portfolio companies across AI, pet health, ageing medicine and more, LongeVC provides venture capital for the biotech and longevity sectors.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Seed, Series A
- Geography: United States, Estonia, Hong Kong
Investor stats
- Total investments: 11
- Lead/follow: no public data
Portfolio highlights
- Melio — Melio has created a rapid, precise, and comprehensive blood test that identifies 99% of the most common pathogens in hours, rather than days.
- Proton Intelligence — Continuous, real-time, and accurate biomarker monitoring to better manage chronic disease and save lives.
- Catena Biosciences — Catena Biosciences uses a novel protein conjugation method to bring breakthroughs in biological therapeutics, autoimmune disorders and vaccine development
Recipharm Venture Fund is part of Recipharm AB.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A
- Geography: Sweden, Switzerland
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- NewBiologix — NewBiologix operates as a technology innovation company, develops a proprietary and breakthroughDNA integration platform for the advanced engineering of human and mammaliancell lines.
- Cinclus Pharma — A Swedish pharma company bringing relief to the world with the clinical stage drug candidate linaprazan glurate for gastric acid related diseases.
Where Entrepreneurs Thrive Rooted in reality, reaching for the extraordinary over five decades of combined investment experience Where Entrepreneurs Thrive Rooted in reality, reaching for the extraordinary Authentic, dedicated, disciplined, and goal-oriented, our team drives meaningful and lasting success About Team
Show more...Investment focus
- Industry: Software, Health Care, Hardware
- Stage:Seed, Series A
- Geography: Switzerland, Italy, France
Investor stats
- Total investments: 18
- Round size: Seed $1.2M–$5.3M; Series A $4.1M–$7M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- Xsensio — Xsensio develops the unique Lab-on-Skin™ sensing platform to sense in real-time biochemical information at the surface of the skin, providing unprecedented real-time information about our health and wellness, in a simple and non-invasive way.The Xsensio Lab-on-Skin™ sensing chip relies on a unique, highly-miniaturized sensing platform developedat the Nanolab of the Swiss Federal Institute of Technology. By leveraging semiconductor properties, our sensing platform unleashes a whole new set of possibilities in continuous health monitoring.
- ENANTIOS — ENANTIOS specializes in creating benchtop analytical instruments that provide industries, research institutions, and academic facilities.
- Hydromea — Hydromea is a Swiss company with core expertise in underwater robotics, through-water wireless communication networks and underwater navigation.
Polytech Ventures are an early stage VC firm based in Switzerland with a strong international focus. Their strategic location at EPFL in Lausanne grants us access to one of the most dynamic and recognized innovation centers in the world
Show more...Investment focus
- Industry: Financial Services, FinTech, Software
- Stage:Seed, Series A
- Geography: Switzerland, United States, Spain
Investor stats
- Total investments: 50
- Round size: Seed $1M–$5M; Series A $2.3M–$9.7M
- Lead/follow: 26% lead, 74% follow
- Last fund: May invest from a new fund soon — raised $40M in 2016
Portfolio highlights
- Relai — All you need to get started is to download our award winning Relai app, complete a simple verification and start buying with as little as 50 CHF/EUR.
- Hemostod — Developing universal platelets and next-generation diagnostics
- Earny — Payroll management built for Startups & SMEs. Swiss payroll service with no hidden fees & no hassle
FiveT is an independent alternative asset manager established in 2006. Starting in 2021, FiveT set out to finance the foundation of the hydrogen economy.
Show more...Investment focus
- Industry: FinTech, Software, Health Care
- Stage:Seed, Convertible Note, Initial Coin Offering
- Geography: United States, Switzerland
Investor stats
- Total investments: 3
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- ZELF — Zelf is a neobank targeting Gen Z to bring financial services to where they live – in messengers. This is the lightest bank with the easiest onboarding process taking up to 60 sec to issue a card, receive and send money without leaving the messenger. We are uniquely offering AI-powered voice control over the most of financial operations, whichmakes us first voice-enabled banking for Gen Z who prefers voice interactions with their devices.
- LimeWire — We are under maintenance.
- PreComb — PreComb develops technologies to optimally adapt the therapies to each patient for difficult to treat cancers to increase the success rates in cancer therapy. Only an efficient use of healthcare resources can lead to a maximum improvement in the quality of life of patients.
Life Science Investor funding in Switzerland at a glance
Stats across 173 deals from 259 investors.
Access all 259 investors in Switzerland Life Science startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Life Science Investors in Switzerland investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 259 investors investing in Switzerland Life Science startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!